Finance

Lists
MVIR:STO
Medivir AB
1,51 SEK
+0,80%
(+0,012) 1D
12 հոկ, 17:29:47 GMT+2  ·   SEK
All symbols
SymbolPriceChange% Change
Generating top insights for MVIR...
Open
1,49 SEK
High
1,51 SEK
Low
1,46 SEK
Mkt. cap
942,54 մլն
Avg. vol.
1,45 մլն
Volume
1,55 մլն
52-wk high
2,88 SEK
52-wk low
0,34 SEK
EPS
-0,37 SEK
Shares outstanding
624,18 մլն
No. of employees
6
Open
1,49 SEK
High
1,51 SEK
Low
1,46 SEK
Mkt. cap
942,54 մլն
Avg. vol.
1,45 մլն
Volume
1,55 մլն
52-wk high
2,88 SEK
52-wk low
0,34 SEK
EPS
-0,37 SEK
Shares outstanding
624,18 մլն
No. of employees
6
News stories
From web sources and news partners
Profile
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies. Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides. Medivir is listed on the Nasdaq Stockholm Mid Cap List. In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
About Medivir AB
CEOChristine Lind
Employees6
Founded1988
Headquarters-
Sector-
Previous reportsAll values in SEK
Loading Previous Earnings...
Revenue
Net income
All values in SEK
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
1,00 մլն
5,51 մլն
1,10 մլն
1,20 մլն
Cost of goods sold
8,10 մլն
10,21 մլն
4,50 մլն
17,90 մլն
Cost of revenue
8,10 մլն
10,21 մլն
4,50 մլն
17,90 մլն
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,80 մլն
7,16 մլն
5,50 մլն
4,30 մլն
Operating expense
6,50 մլն
37,66 մլն
6,20 մլն
4,50 մլն
Total operating expenses
14,60 մլն
47,88 մլն
10,70 մլն
22,40 մլն
Operating income
-13,60 մլն
-42,37 մլն
-9,60 մլն
-21,20 մլն
Other non operating income
-
-500,00 հզր
200,00 հզր
-
EBT including unusual items
-14,60 մլն
-43,20 մլն
-9,40 մլն
-20,10 մլն
EBT excluding unusual items
-14,60 մլն
-43,77 մլն
-9,40 մլն
-20,10 մլն
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-7,00 հզր
-
200,00 հզր
Net income
-14,60 մլն
-43,20 մլն
-9,40 մլն
-20,10 մլն
Net profit margin
-1 460,00%
-784,60%
-854,55%
-1 675,00%
Earnings per share
-0,13
-
-
-
Interest and investment income
-
41,00 հզր
-
1,10 մլն
Interest expense
-1,00 մլն
-1,31 մլն
-
-
Net interest expenses
-1,00 մլն
-1,27 մլն
-
1,10 մլն
Depreciation and amortization charges
700,00 հզր
30,51 մլն
700,00 հզր
-
EBITDA
-12,90 մլն
-11,87 մլն
-8,90 մլն
-20,90 մլն
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google Apps